Key facts
- LumiThera’s last known valuation is $90.0M (Feb 2025).
- It has raised $39.3M across 8 recorded rounds; the latest was Early Stage VC ($10.0M) in May 2024.
- LumiThera has filed 15 Form Ds with the SEC since 2014, most recently Feb 2025 ($10.0M sold to 58 investors).
- Status: Acquired/Merged (Operating Subsidiary).
- ·Post-money valuations for all 8 rounds
- ·Watchlist + deal alerts for LumiThera
Funding rounds
8 roundsAbout LumiThera
Developer of medical devices intended to prevent vision loss and blindness. The company's offerings include photobiomodulation treatments using non-invasive light-emitting diodes for acute and chronic ocular diseases and disorders, improving visual acuity and contrast sensitivity and reducing central drusen volume, enabling healthcare providers to provide better treatment for dry age-related muscular degeneration.
- Sector
- Healthcare
- HQ
- Poulsbo, WA, United States
- Founded
- 2013
- Employees
- 21
- Website
- lumithera.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
LumiThera doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LumiThera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LumiThera in its N-PORT filings yet. We sweep new filings monthly.